 |
您当前的位置：电子期刊栏目→论著>>正文 |
| 卵巢癌组织hsa-miR-28表达及其临床意义 |
| 作者：李琼英1 郭玲2 王恺彬1 |
| 单位：1. 宝鸡市中心医院 妇科, 陕西 宝鸡 721000; 2. 咸阳市第一人民医院 病理科, 陕西 咸阳 712000 |
| 关键词：卵巢癌 内含子型微小核糖核酸-28 病理特征 复发 |
| 分类号：R737.31 |
| 出版年·卷·期（页码）：2023·42·第二期（246-251） |
| 摘要： |
目的:探讨卵巢癌组织内含子型微小核糖核酸-28(hsa-miR-28)表达及其与临床病理特征及根治术后复发的关系。方法:选取2017年3月至2019年3月宝鸡市中心医院收治的行根治术治疗的138例卵巢癌患者作为卵巢癌组,选取同期行腹腔镜治疗的120例卵巢良性病变患者作为对照组,检测两组患者切除卵巢组织的hsa-miR-28表达水平,并比较卵巢癌不同病理特征患者卵巢组织hsa-miR-28表达水平。随访3年,记录卵巢癌根治术后复发情况,比较复发和未复发患者hsa-miR-28表达水平,并采用Cox回归分析卵巢癌根治术后复发的影响因素。结果:卵巢癌组卵巢组织hsa-miR-28表达水平低于对照组(2.24±0.62 vs. 4.12±0.73,P＜0.001);低分化、FIGO分期Ⅲ期卵巢癌患者hsa-miR-28表达水平低于高/中分化、FIGO分期Ⅰ~Ⅱ期患者(1.72±0.31 vs. 2.70±0.54、1.79±0.34 vs. 2.53±0.66,P＜0.05)。随访3年期间138例卵巢癌患者有49例复发,复发率为35.51%,复发组低分化、FIGO分期Ⅲ期占比均高于未复发组(P＜0.05),复发组术后化疗患者占比及hsa-miR-28表达水平低于未复发组(P＜0.05); Cox分析结果显示,hsa-miR-28低表达、低分化、FIGO分期Ⅲ期均是卵巢癌根治术后复发的危险因素,术后化疗是其保护因素(P＜0.05)。结论:hsa-miR-28在卵巢癌组织中呈低表达,且与卵巢癌临床病理特征及根治术后复发密切相关,检测hsa-miR-28表达水平对于评估卵巢癌病情进展及预后可能具有潜在的临床价值。 |
Objective: To investigate the expression of hsa-miR-28 in ovarian cancer tissues and its relationship with clinicopathological features and recurrence after radical resection. Methods: 138 patients with ovarian cancer who were treated by radical resection in Baoji Central Hospital from March 2017 to March 2019 were selected as the ovarian cancer group, and 120 patients with benign ovarian lesions who were treated by laparoscopy at the same time were selected as the control group. Ovarian tissues excised from the two groups were collected to detect the expression level of hsa-miR-28, and the expression levels of hsa-miR-28 in ovarian tissues of patients with ovarian cancer with different pathological characteristics were compared. The patients with ovarian cancer were followed up for 3 years, and the recurrence of patients after radical resection was recorded. The expression levels of hsa-miR-28 were compared between recurrent and non-recurrent patients, and the influencing factors of recurrence after radical resection were analyzed by Cox regression. Results: The expression level of hsa-miR-28 in ovarian tissue of ovarian cancer group was lower than that of the control group(2.24±0.62 vs. 4.12±0.73,P<0.001). The expression levels of hsa-miR-28 in ovarian cance patients with poorly differentiated and FIGO stage Ⅲ were lower than those in patients with well/moderately differentiated and FIGO stage Ⅰ~Ⅱ(1.72±0.31 vs.2.70±0.54, 1.79±0.34 vs. 2.53±0.66,P<0.05). During the follow-up period of 3 years, 49 patients relapsed, and the recurrence rate was 35.51%. The proportion of poorly differentiated and FIGO stage Ⅲ in the recurrence group were higher than those in the non-recurrence group(P<0.05), and the proportion of postoperative chemotherapy patients and the expression level of hsa-miR-28 in the recurrence group were lower than those in the non-recurrence group(P<0.05). Cox analysis showed that low expression of hsa-miR-28, low differentiation and FIGO stage Ⅲ were the risk factors of recurrence after radical resection of ovarian cancer, while postoperative chemotherapy was a protective factor(P<0.05). Conclusion: The expression of hsa-miR-28 is low in ovarian cancer, which is closely related to the clinicopathological features of ovarian cancer and the recurrence after radical resection, detecting the expression level of hsa-miR-28 may have potential clinical value in evaluating the progress and the prognosis of ovarian cancer. |
| 参考文献： |
[1] YIN L,ZHANG N,YANG Q.DNA methylation subtypes for ovarian cancer prognosis[J].FEBS Open Bio,2021,11(3):851-865. |
| 服务与反馈： |
| 【文章下载】【发表评论】【查看评论】【加入收藏】 |
| 提示：您还未登录，请登录！点此登录 |
|
|||
|
|